<DOC>
	<DOCNO>NCT01948960</DOCNO>
	<brief_summary>A study determine whether everolimus pharmacokinetics elderly obese patient different compare control patient . Furthermore investigator investigate relation metabolic response assess [ 18F ] Fluorodeoxyglucose-Positron Emission Tomography ( FDG-PET ) everolimus exposure clinical benefit . The investigator explore whether dose escalation patient hypothetically underexposed result increase metabolic response .</brief_summary>
	<brief_title>Influence Exceptional Patient Characteristics Everolimus Exposure</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult woman ( ≥ 18 year age ) metastatic locally advanced breast cancer amenable curative treatment surgery radiotherapy . Histological cytological confirmation estrogenreceptor positive ( ER+ ) breast cancer Postmenopausal woman Radiological clinical evidence recurrence progression last systemic therapy prior enrollment . Progression follow nonsteroidal aromatase inhibitor Falling one follow category elderly patient ( age ≥ 70 year BMI &lt; 30 kg/m2 ) ; obese patient ( BMI ≥ 30 kg/m2 age &lt; 70 year ) ; control patient ( BMI &lt; 30 kg/m2 age &lt; 70 year ) ; Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5 x ULN Adequate renal function : calculated creatinine clearance , estimate GFR use MDRD formula , ≥ 30ml/min/1.73m2 Performance status ECOG 0 2 ( Karnofsky index : 60 100 ) Patient willing able sign Informed Consent Form prior screen evaluation Patients age ≥ 70 year AND BMI ≥ 30 kg/m2 HER2overexpressing patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Previous treatment exemestane mTOR inhibitor . Except treatment exemestane adjuvant setting . Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) . Patients known history HIV seropositivity . Any severe / uncontrolled medical condition : Unstable angina pectoris , serious uncontrolled cardiac arrhythmia Patients severe hepatic impairment ( ChildPugh A/B/C ) Uncontrolled diabetes mellitus Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Patients test positive hepatitis B C Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A within last 5 day prior enrollment History noncompliance medical regimens Patients unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>everolimus</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>elderly patient</keyword>
	<keyword>obese patient</keyword>
</DOC>